Evidence map›Paper›PMID 41552349›Full record

ArticleAmerican journal of translational research2025

Clinical outcomes of lenalidomide, bortezomib, and dexamethasone in multiple myeloma patients.

Lu Yu, Lirong Ren, Zheng Hou, Yang Yang, Kaiji Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lu YuDepartment of Hematology, Chengdu First People's Hospital Chengdu 610000, Sichuan, China.
Lirong RenDepartment of Hematology, Chengdu First People's Hospital Chengdu 610000, Sichuan, China.
Zheng HouDepartment of Hematology, Chengdu First People's Hospital Chengdu 610000, Sichuan, China.
Yang YangDepartment of Hematology, Chengdu First People's Hospital Chengdu 610000, Sichuan, China.
Kaiji ZhangDepartment of Hematology, Chengdu First People's Hospital Chengdu 610000, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the clinical benefits of the combination therapy involving lenalidomide, bortezomib, and dexamethasone in treating multiple myeloma (MM).

methodsThis retrospective analysis included 182 patients with MM treated between January 2022 and June 2025. The patients were divided into a Lenalidomide group (n=93) and a control group (n=89). Before and after treatment, lactate dehydrogenase (LDH), β

resultsThe Lenalidomide group showed a significantly better therapeutic response than the control group (

conclusionLenalidomide, bortezomib, and dexamethasone, demonstrate significant clinical efficacy in treating multiple myeloma.

Indexed as

bortezomibcurative effectdexamethasonelenalidomideMultiple myeloma

Identifiers

PMID41552349
PMCPMC12808043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.